PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application CLL - Market size and forecast 2018-2023 FL - Market size and forecast 2018-2023 Other indications - Market size and forecast 2018-2023 Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Expansion of research indications Reimbursement programs Growing awareness about cancer PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bayer AG Gilead Sciences Inc. Novartis AG TG Therapeutics Inc. Verastem Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Application - Market share 2018-2023 (%) Exhibit 18: Comparison by application Exhibit 19: CLL - Market size and forecast 2018-2023 ($ millions) Exhibit 20: CLL - Year-over-year growth 2019-2023 (%) Exhibit 21: FL - Market size and forecast 2018-2023 ($ millions) Exhibit 22: FL - Year-over-year growth 2019-2023 (%) Exhibit 23: Other indications - Market size and forecast 2018-2023 ($ millions) Exhibit 24: New cases of cancer in US 2015 Exhibit 25: Other indications - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by application Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Proportion of geriatric population in Asia 2007 and 2017 Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Drug designations Exhibit 46: Impact of drivers and challenges Exhibit 47: Approved drugs with respect to their cancer indications Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: Bayer AG - Vendor overview Exhibit 54: Bayer AG - Product segments Exhibit 55: Bayer AG - Organizational developments Exhibit 56: Bayer AG - Geographic focus Exhibit 57: Bayer AG - Segment focus Exhibit 58: Bayer AG - Key offerings Exhibit 59: Bayer AG - Key customers Exhibit 60: Gilead Sciences Inc. - Vendor overview Exhibit 61: Gilead Sciences Inc. - Business segments Exhibit 62: Gilead Sciences Inc. - Organizational developments Exhibit 63: Gilead Sciences Inc. - Geographic focus Exhibit 64: Gilead Sciences Inc. - Key offerings Exhibit 65: Gilead Sciences Inc. - Key customers Exhibit 66: Novartis AG - Vendor overview Exhibit 67: Novartis AG - Business segments Exhibit 68: Novartis AG - Organizational developments Exhibit 69: Novartis AG - Geographic focus Exhibit 70: Novartis AG - Segment focus Exhibit 71: Novartis AG - Key offerings Exhibit 72: Novartis AG - Key customers Exhibit 73: TG Therapeutics Inc. - Vendor overview Exhibit 74: TG Therapeutics Inc. - Business segments Exhibit 75: TG Therapeutics Inc. - Organizational developments Exhibit 76: TG Therapeutics Inc. - Key offerings Exhibit 77: TG Therapeutics Inc. - Key customers Exhibit 78: Verastem Inc. - Vendor overview Exhibit 79: Verastem Inc. - Business segments Exhibit 80: Verastem Inc. - Organizational developments Exhibit 81: Verastem Inc. - Key offerings Exhibit 82: Verastem Inc. - Key customers Exhibit 83: Validation techniques employed for market sizing Exhibit 84: Definition of market positioning of vendors

Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc.